FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)

Kalshi Health › FDA & drugs Closes Dec 31 · $3.7K traded · $1.2K at stake · prices read 3 h ago

The odds

92%chance

How the odds have moved

Yes: 89% on Oct 20, 92% now.

Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.

Every outcome

Outcome	Chance	Day	Bid	Ask	Pays	Contracts
Yes	92%		88¢	95¢	$1.05	4.1K

"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".

The news: FDA, Anitocabtagene Autoleucel, Gilead Sciences

Search ›

Gilead Sciences (GILD) Receives a Buy from TD CowenThe Globe and Mail · 30 h agoDetailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades. TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences today and set a price target of $160.00. Van…
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?The Motley Fool · 13 h agoStocks in some sectors and industries are known for paying dividends. Consumer staples, energy, and utility stocks are great examples. However, the biotech industry isn't in the group. Most biotech companies are small and can't afford to…
Gilead Sciences, Inc. $GILD Stock Holdings Increased by Sterling Capital Management LLCMarkets Daily · 30 h agoPosted by Mitch Edgeman on Oct 24th, 2026 The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were paid a $0.82 dividend. The ex-dividend date…
Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting UpdateYahoo Finance · 47 h agoGilead Sciences (GILD) is back in focus after outlining new data it plans to showcase at The Liver Meeting 2026 on its liver disease drugs Livdelzi and Hepcludex, drawing fresh attention to the depth of its pipeline. Recent news has landed…
Gilead Sciences, Inc. $GILD Stock Bought by Royal Fund Management LLCMarkets Daily · 2 days agoPosted by Kim Johansen on Oct 23rd, 2026 The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were given a dividend of $0.82 per share. This…
Gilead Sciences, Inc. $GILD Stock: AMF Tjanstepension AB Lowers HoldingsMarketBeat · 3 days agoView Our Latest Research Report on GILD Shares of NASDAQ GILD opened at $157.19 on Friday. Gilead Sciences, Inc. has a 12 month low of $114.02 and a 12 month high of $160.51. The firm's 50 day simple moving average is $148.74 and its…
Gilead Sciences to Acquire PepStar's Oral Inflammation Drug Program for $1.28 BillionMarketScreener · 3 days agoGilead Sciences agreed to acquire an investigational oral inflammation drug program, including lead asset HCXT-2001, from PepStar Therapeutics for $1.28 billion in cash, the company said... Gilead Sciences to Acquire PepStar's Oral…
Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement, Attorney General Paxton SaysMarketScreener · 3 days agoGilead Sciences agreed to pay $45 million to settle claims by Texas Attorney General Ken Paxton that it engaged in an illegal kickback scheme that improperly influenced prescriptions covered by... Gilead Sciences to Pay $45 Million in…
Gilead Sciences, Inc. Presents New Data On Livdelzi And Hepcludex At The Liver Meeting 2026MarketScreener · 3 days agoGilead Sciences, Inc. announced that it will present new clinical and real-world evidence across primary biliary cholangitis and chronic hepatitis delta virus infection at The Liver Meeting® 2026,...
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?Yahoo Finance · 3 days agoYahoo Finance Oops, something went wrong Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions? Is GILD a good stock to buy? We came across a bullish thesis on Gilead…
Gilead Sciences (GILD) Settles $45M Medicaid Kickback Allegations in Texas@gurufocus · 3 days agoThe GF Score™ is a composite metric designed to assess a company’s overall financial health by integrating factors such as profitability, growth, financial strength, valuation, and momentum. Gilead’s GF Score™ of 71/100 indicates a…
BioNTech SE Advances Phase 3 Clinical Trial Of Pumitamig In Combination With Gilead Sciences Inc.?s TROP2-Directed ADC Sacituzumab Govitecan In Triple-Negative Breast CancerMarketScreener · 2 days agoPublished on 10/22/2026 at 06:45 am EDT BioNTech: Q2 miss, followed by a sales guidance downgrade August 04, 2026 at 12:07 pm EDT BioNTech rocked on the stock market by the departure of its legendary founder couple BioNTech’s…

Related markets

All fda & drugs ›

Health › FDA & drugs

Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)

17%chance▲ 2

Health › FDA & drugs

When will Beam Therapeutics submit a BLA for Risto-cel?

72%before April 2027

before April 202772%
before 202751%
before December29%▼ 2

1 more

before November3%

Health › FDA & drugs

When will the FDA reclassify BPC-157 to Category 1?

21%Before 2027

Before 202721%
Before November7%▼ 1

Health › FDA & drugs

When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)

96%before 2027

before 202796%
before April 202783%
before December42%▼ 2

1 more

before November8%▼ 1

Health › FDA & drugs

When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)

88%Before 2028

Before 202888%▼ 1
Before July 202785%
Before October 202785%▼ 1

2 more

Before Mar 1, 202762%▼ 1
Before Jan 1, 202724%▼ 1

Health › FDA & drugs

Will the FDA approve retatrutide? (retatrutide (LY3437943))

Oct 22, 2027even chance by

Before Jan 1, 20274%
Before Jul 1, 202718%
Before Jan 1, 202871%

2 more

Before Jul 1, 202885%
Before Jan 1, 202990%

Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Search. Prices read from the venues 4 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.

About this market

VenueKalshi

Settles onAppliedXL

Trading closesDec 31, 2026 11:59 PM ET

Traded$3.7K (4,058 contracts)

This week$144

At stake$1.2K

In the news52 headlines today, 825 this week

Followed here sinceOct 19, 2026

The rules

If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

The full rules are on the market's page at Kalshi.

Reading the odds

A prediction market trades contracts that pay $1 if something happens. Its price is the market's chance: a contract at 62¢ means traders give it 62%. Each number here is the midpoint between the best bid and offer, or the last trade when they are more than ten cents apart.

For a question with many answers (who wins, which range a number lands in), the chances are scaled to add up to 100%. A price ladder ("above 4.25%, above 4.50% ...") gives a whole distribution: its median is where traders see an even chance either way.

Kalshi is a U.S. exchange regulated by the CFTC; its money is counted in contracts, shown here as dollars at their price. Polymarket counts dollars. ForecastEx is Interactive Brokers' exchange, regulated by the CFTC; its contracts too are shown as dollars at their price. Crypto.com lists its markets on Crypto.com | Derivatives North America, a U.S. exchange regulated by the CFTC; it reports the dollars traded. Where more than one asks the same question, each is shown, never averaged.

Prefer betting odds? Switch to American (+150) or decimal (2.50) odds at the top of the page.

Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Search, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Search index; prices of stocks, rates and coins from 4Search Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions